Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine. (Q40004108)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Sukru Tuzmen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

6

Noel Pabalan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1

Hamdi Jarjanazi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Jeffrey Kiefer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Laurent Briollais

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Irada Ibrahim-Zada

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Spyro Mousses

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Hilmi Ozcelik

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

461-467

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18330920%20AND%20SRC:MED&resulttype=core&format=json

Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Haploview: analysis and visualization of LD and haplotype maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Rad18 regulates DNA polymerase kappa and is required for recovery from S-phase checkpoint-mediated arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Definition and clinical importance of haplotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

High-resolution haplotype structure in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

The Gene Ontology (GO) project in 2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Genetic testing for pharmacogenetics and its clinical application in drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

A haplotype map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

DNA polymerases as targets of anticancer nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Combined modality therapy of gemcitabine and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

PLINK: a tool set for whole-genome association and population-based linkage analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Summary of information on human CYP enzymes: human P450 metabolism data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Pharmacogenetics and the concept of individualized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

The NCI60 human tumour cell line anticancer drug screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Cancer pharmacogenomics: international trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

Folate and carcinogenesis: evidence, mechanisms, and implications

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20732

7 January 2021